...Aleksandra Leszczynska; Jolanta Grzenkowicz-Wydra; Lidia Chmielewska-Gorycka; Maria Bieniaszewska; Andrzej Hellmann Introduction: The identification of mutations of the JAK2 gene is a useful marker in the diagnosis of polycythemia vera (PV) patients. We studied the frequency of JAK2 mutations...

... JAK2 mutation Tyrosine kinase inhibitors Chronic myeloproliferative neoplasms (CMPNs) are rare diseases of hematopoietic stem cells that are characterized by clonal expansion of one or more myeloid precursor cells. The four most frequent diseases of this group are chronic myelogenous leukemia...

... JAK2 V617F and may exhibit substantial overlap. Variability in JAK activation and allele burden, complemented by host, genetic and non-genetic modifiers, determine the phenotype. The aim of this study was to investigate the presence of the JAK2 mutation in association with the ratio...

.... Essential thrombocythemia Polycythemia vera JAK2 mutation Unusual splanchnic or cerebral vein thrombosis Heparin-induced thrombocytopenia Over the last 10 years, we selected 29 patients with Ph-MPD (9 males and 20 females; 9 with polycythemia vera, PV, and 20 with essential thrombocythemia, ET...

... in this unusual site in patients with ET, but the existence of a specific association between unexplained SVT and the JAK2 mutation has been reported. Methods and Results: The present study describes SVT (portal and splenic vein thrombosis) in a young woman as the first presenting symptom of latent ET. Extensive...